摘要
目的:探讨不同剂量伐地那非治疗新生儿持续肺动脉高压的临床疗效。方法:选择2013年8月~2017年4月在本院确诊并接受治疗的持续肺动脉高压新生儿60例,均接受伐地那非治疗并根据药物剂量不同分为低剂量组(2.5mg)、中等剂量组(5mg)、大剂量组(10mg),各20例。对比3组患儿治疗1个月后肺动脉收缩压(PASP)水平,外周血中心肌损伤标志物、内皮损伤指标含量的差异。结果:治疗1个月后,大剂量组患儿的PASP水平低于中等剂量组、低剂量组;外周血中心肌损伤标志物高敏肌钙蛋白T(hs-cTnT)、B型尿钠肽(BNP)、乳酸脱氢酶(LDH)含量低于中等剂量组、低剂量组;外周血中内皮损伤指标内皮素-1(ET-1)、缺氧诱导因子-1α(HIF-1α)含量低于中等剂量组、低剂量组,肾上腺髓质(ADM)、一氧化氮(NO)含量高于中等剂量组、低剂量组。中等剂量组中上述指标水平变化趋势大于低剂量组。差异均有统计学意义(P<0.05)。结论:伐地那非是临床治疗新生儿持续肺动脉高压的可靠药物,且药效呈一定剂量依赖性。
Objective:To explore the clinical efficacy of different doses of vardenafil for the treatment of neonatal persistent pulmonary hypertension.Methods:60 neonates with persistent pulmonary hypertension were diagnosed and treated in this hospital between August 2013 and April 2017,all of them received vardenafil therapy and they were divided into low dose group(2.5 mg),medium dose group(5 mg)and high dose group(10 mg)according to the doses,20 cases in each group.The differences in pulmonary arterial systolic pressure(PASP)levels as well as the contents of myocardial injury markers and endothelial injury indexes were compared among the three groups of children after 1 month of treatment.Results:After 1 month of treatment,the PASP level in high dose group was lower than that in medium dose group and low dose group;myocardial injury markers hs-cTnT,BNP and LDH contents in peripheral blood were lower than those of medium dose group and low dose group;endothelial injury indexes ET-1 and HIF-1αcontents in peripheral blood were lower than those of medium dose group and low dose group whereas ADM and NO contents were higher than those of medium dose group and low dose group.The change trend of the above indicators in medium dose group was greater than that in low dose group.Conclusion:Vardenafil is a reliable drug for clinical treatment of neonatal persistent pulmonary hypertension,and the efficacy is dose-dependent.
出处
《海南医学院学报》
CAS
2018年第4期552-555,共4页
Journal of Hainan Medical University
基金
绵阳市中心医院院级课题(2012YJ05)~~
关键词
新生儿持续肺动脉高压
伐地那非
肺动脉收缩压
心肌损伤
内皮损伤
neonatal persistent pulmonary hypertension
vardenafil
pulmonary arterial systolic pressure
myocardial injury
endothelial injury
